IceCure Medical Ltd – Cashflow (NASDAQ:ICCM) | MetaTrader

Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik

Vierteljährlich Jährlich

Mittelzufluss aus laufender Geschäftstätigkeit -12.61 M-14.29 M-12.52 M-12.56 M—-14.57 M -30.64 M Mittelzufluss aus Investitionstätigkeit 3.79 M-891 K-713 K446 K—-36 K — Zahlungsströme aus der Finanzierungstätigkeit 30.89 M13.58 M83 K9.19 M—15.83 M — Freier Cashflow -13.14 M-15.18 M-13 M-12.63 M—-14.61 M -30.64 M

Nachrichten

IceCure Medical Ltd (ICCM) Q4 2025 Earnings Call Transcript

IceCure Medical schedules special shareholder meeting for January 2026

Nvidia, Target, TJX, and more set to report earnings Wednesday

Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates

Acadia Healthcare (ACHC) Beats Q3 Earnings and Revenue Estimates

IceCure Medical: Positive Studienergebnisse zur Kryoablation lassen Aktie steigen

IceCure Medical stock jumps after cryoablation study shows improved survival rates

Freezing Cancer With IceCure: ProSense Cryoablation System Receives FDA Marketing Authorization For Early-Stage Breast Cancer Treatment - Icecure Medical (NASDAQ:ICCM)

IceCure Medical: H.C. Wainwright hebt Kursziel nach FDA-Zulassung auf 2,50 US-Dollar an

IceCure Medical stock price target raised to $2.50 from $2.00 at H.C. Wainwright

IceCure Medical Ltd (ICCM) U.S. FD&A's MarketingAuthorizationforProSenseCryoablation Call

ICCM Shares Rise as FDA Clears ProSense for Breast Cancer Treatment